Increasingly, accused infringers challenge a patent’s validity in two different forums: in litigation in federal court and in post-issuance review at the Patent and Trademark Office (PTO). These parallel proceedings have produced conflicting and controversial results. For example, in one recent case, a district court rejected a challenge to a patent’s validity and awarded millions of dollars in damages for infringement. The Federal Circuit initially affirmed those rulings, ending the litigation over the patent’s validity. In a subsequent appeal about royalties owed by the infringer, however, the Federal Circuit vacated the entire judgment — including the validity ruling and damages award it had previously affirmed — because the PTO had sinc...
Since the 1980s, the United States Patent and Trademark Office has amended or revoked patents throug...
Most patent scholars agree that the Patent and Trademark Office grants too many invalid patents and ...
MedImmune, Inc. v. Genentech, Inc. asks whether Article III\u27s restriction on the jurisdiction of ...
Increasingly, accused infringers challenge a patent’s validity in two different forums: in litigatio...
Increasingly, accused infringers challenge a patent’s validity in two different forums: in litigatio...
Most patent scholars agree that the Patent and Trademark Office grants too many invalid patents and ...
Most patent scholars agree that the Patent and Trademark Office grants too many invalid patents and ...
For more than two decades, the Patent and Trademark Office (PTO) and the Federal Circuit have exerci...
For more than two decades, the Patent and Trademark Office (PTO) and the Federal Circuit have exerci...
Most patent scholars agree that the Patent and Trademark Office grants too many invalid patents and ...
Deciding a patent’s validity is costly, and so is deciding it incorrectly. Judges and juries must ex...
Historically, patent litigation has been viewed and treated primarily as private law litigation, as ...
We analyze how new information about the validity of a patent impacts the settlement of patent infri...
A lengthy tug of war between the Supreme Court and the Federal Circuit Court of Appeals may have end...
Since the 1980s, the United States Patent and Trademark Office has amended or revoked patents throug...
Since the 1980s, the United States Patent and Trademark Office has amended or revoked patents throug...
Most patent scholars agree that the Patent and Trademark Office grants too many invalid patents and ...
MedImmune, Inc. v. Genentech, Inc. asks whether Article III\u27s restriction on the jurisdiction of ...
Increasingly, accused infringers challenge a patent’s validity in two different forums: in litigatio...
Increasingly, accused infringers challenge a patent’s validity in two different forums: in litigatio...
Most patent scholars agree that the Patent and Trademark Office grants too many invalid patents and ...
Most patent scholars agree that the Patent and Trademark Office grants too many invalid patents and ...
For more than two decades, the Patent and Trademark Office (PTO) and the Federal Circuit have exerci...
For more than two decades, the Patent and Trademark Office (PTO) and the Federal Circuit have exerci...
Most patent scholars agree that the Patent and Trademark Office grants too many invalid patents and ...
Deciding a patent’s validity is costly, and so is deciding it incorrectly. Judges and juries must ex...
Historically, patent litigation has been viewed and treated primarily as private law litigation, as ...
We analyze how new information about the validity of a patent impacts the settlement of patent infri...
A lengthy tug of war between the Supreme Court and the Federal Circuit Court of Appeals may have end...
Since the 1980s, the United States Patent and Trademark Office has amended or revoked patents throug...
Since the 1980s, the United States Patent and Trademark Office has amended or revoked patents throug...
Most patent scholars agree that the Patent and Trademark Office grants too many invalid patents and ...
MedImmune, Inc. v. Genentech, Inc. asks whether Article III\u27s restriction on the jurisdiction of ...